Women's Health Concerns Clinic, St. Joseph's Healthcare, 301 James Street South, Hamilton, ON, L8P 3B6, Canada.
CNS Drugs. 2013 Aug;27(8):583-9. doi: 10.1007/s40263-013-0069-7.
Premenstrual dysphoria (PMD) affects 3-8 % of women in their reproductive years worldwide. This paper summarizes the studies establishing the efficacy of continuous, luteal phase, and symptom-onset dosing of selective serotonin reuptake inhibitors (SSRIs) and dual serotonin and norepinephrine reuptake inhibitors (SNRIs) in treating women with PMD. The evidence indicates that for some women, symptom-onset dosing with escitalopram, fluoxetine, and paroxetine controlled release (CR) is as effective as continuous or luteal phase dosing. The wide range of clinical efficacy of SSRIs/SNRIs suggests that they exert their therapeutic effect through multiple pathways. This paper offers a few alternative mechanisms of action to explain the rapid response to SSRIs/SNRIs in women with PMD.
经前期烦躁障碍（PMD）影响全球生育年龄的 3-8%的女性。本文总结了研究建立了连续，黄体期和症状发作剂量选择性血清素再摄取抑制剂（SSRIs）和双重血清素和去甲肾上腺素再摄取抑制剂（SNRIs）在治疗 PMD 女性中的疗效。证据表明，对于某些女性，依地普仑，氟西汀和帕罗西汀控释（CR）的症状发作剂量与连续或黄体期剂量一样有效。SSRIs/SNRIs 的广泛临床疗效表明它们通过多种途径发挥治疗作用。本文提供了一些替代作用机制来解释 PMD 女性对 SSRIs/SNRIs 的快速反应。
